Form 4: ResMed Director Peter C. Farrell Reports Acquisition of Restricted Stock Units

ResMed director Peter C. Farrell acquired 542 restricted stock units on November 20, 2024.

Summary

• Peter C. Farrell, a director at ResMed Inc., reported acquiring 542 shares of ResMed common stock in the form of restricted stock units (RSUs).
• The transaction occurred on November 20, 2024.
• The RSUs were awarded at a price of $0.
• Following the transaction, Mr. Farrell beneficially owns 83,218 shares of ResMed common stock.
• The RSUs cliff vest on the earlier of November 11, 2025, or the annual shareholder's meeting in the year following the grant date.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock awards to a director, which is generally viewed as a neutral to slightly positive event, indicating alignment of interests between management and shareholders.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to stock-based compensation for a company director, which is common practice in publicly traded companies.

Comparison to Industry Standards

• Stock-based compensation, such as restricted stock units, is a common practice for directors and executives in publicly traded companies like ResMed.
• The vesting schedule of the RSUs, with a cliff vesting date, is also a standard practice to incentivize long-term commitment and performance.
• Comparable companies in the medical device industry, such as Medtronic and Stryker, also utilize similar stock-based compensation plans for their directors and executives.

Stakeholder Impact

• The acquisition of restricted stock units by a director can be seen as a positive sign for shareholders, indicating confidence in the company's future performance.

Key Dates

Keywords

ResMed, Director, Peter C. Farrell, Restricted Stock Units, RSU, Stock Acquisition, Beneficial Ownership, SEC Form 4